Cargando…

The effect of lemborexant for insomnia disorder

BACKGROUND: Lemborexant has a low dependence potential, less muscle relaxant effect, and less effect on cognitive function. However, there have been no naturalistic reports in Japan clarifying the effect of lemborexant on insomnia disorder. We retrospectively examined the effectiveness of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Hidenobu, Hibino, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377315/ https://www.ncbi.nlm.nih.gov/pubmed/34422270 http://dx.doi.org/10.1177/20503121211039098

Ejemplares similares

Characteristics of patients who were able to switch from benzodiazepine hypnotics to lemborexant
por: Suzuki, Hidenobu, et al.
Publicado: (2021)

Lemborexant for insomnia
Publicado: (2021)

Efficacy and safety of lemborexant in midlife women with insomnia disorder
por: Terauchi, Masakazu, et al.
Publicado: (2023)

PSUN201 Efficacy and Safety of Lemborexant in Diabetic Patients With Insomnia Disorder
por: Moline, Margaret, et al.
Publicado: (2022)

Pilot Study of Lemborexant for Insomnia in Cancer Patients with Delirium
por: Terada, Tatsuto, et al.
Publicado: (2022)

Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder
por: Dash, Amitabh, et al.
Publicado: (2022)

Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial
por: Takaesu, Yoshikazu, et al.
Publicado: (2023)

Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study
por: Mayleben, David, et al.
Publicado: (2021)

Comparison of the effect of lemborexant and other insomnia treatments on driving performance: a systematic review and meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial
por: Rosenberg, Russell, et al.
Publicado: (2019)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

P096 Subjective ratings of medication strength of lemborexant over 6 months in subjects with moderate or severe insomnia
por: Drake, C, et al.
Publicado: (2021)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents
por: Ikeda, Shunya, et al.
Publicado: (2022)

P097 Incidence of abnormal dreams and nightmares with lemborexant in adults with insomnia: results from two Phase 3 studies
por: Roth, T, et al.
Publicado: (2021)

Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
por: Kärppä, Mikko, et al.
Publicado: (2020)

Can Lemborexant for Insomnia Prevent Delirium in High-Risk Patients with Pancreato-Biliary Disease after Endoscopic Procedures under Deep Sedation?
por: Ogura, Takeshi, et al.
Publicado: (2022)

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
por: Landry, Ishani, et al.
Publicado: (2020)

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: A model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents – CORRIGENDUM
por: Ikeda, Shunya, et al.
Publicado: (2022)

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
por: Khazaie, Habibolah, et al.
Publicado: (2022)

FLUID study: study protocol for an open-label, single-centre pilot study to investigate the efFect of Lemborexant on sleep management in Japanese sUbjects aged 50 years and older with Insomnia Disorder
por: Okada, Ippei, et al.
Publicado: (2021)

Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
por: Landry, Ishani, et al.
Publicado: (2022)

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
por: Ueno, Takashi, et al.
Publicado: (2021)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer’s Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant
por: Beuckmann, Carsten T., et al.
Publicado: (2021)

Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation
por: Beuckmann, Carsten Theodor, et al.
Publicado: (2019)

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
por: Vermeeren, Annemiek, et al.
Publicado: (2018)

One patient with schizophrenia showed reduced drug-induced extrapyramidal symptoms as a result of an alternative regimen of treatment with paliperidone 3 and 6 mg every other day
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Erratum to: On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
por: Vermeeren, Annemiek, et al.
Publicado: (2020)

Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females
por: Landry, Ishani, et al.
Publicado: (2021)

Effect of insomnia in the major depressive disorder
por: Xu, Guohong, et al.
Publicado: (2022)

The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
por: Moline, Margaret, et al.
Publicado: (2023)

Musculoskeletal disorders increases the insomnia severity in nurses
por: Cici, Remziye, et al.
Publicado: (2022)

Is insomnia disorder associated with time in bed extension?
por: Birling, Yoann, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_64cqjm23qml80ebhhf6skb1q8n